Health
Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
PRINCETON, N.J., August 25, 2025--Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/c440ed0864c87dedbaf473f93db7b2f5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7Y8QXBawBD4N9d_IiD0oPQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c440ed0864c87dedbaf473f93db7b2f5","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/9hUGMDWieaJa6Q94NBL9fQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c440ed0864c87dedbaf473f93db7b2f5","width":1200,"height":165}},"lazy":false},{"type":"text","content":"Camzyos (mavacamten) presentations include real-world outcomes from COLLIGO-HCM and a pooled monotherapy analysis from four Phase 3 studies","length":139,"tagName":"p","attribs":{}},{"type":"text","content":"Results add to growing body of evidence supporting the efficacy and safety profile of this first and only approved cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy","length":195,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., August 25, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 29 – September 1, 2025, in Madrid, Spain. Data to be presented at the meeting include new real-world analyses of Camzyos (mavacamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) as well as data on behalf of the BMS-Pfizer Alliance on Eliquis (apixaban).","length":546,"tagName":"p"},{"type":"text","content":""With a 70-year legacy in cardiovascular medicine, we are deeply committed to advancing life-changing therapies for patients, including those living with symptomatic obstructive HCM," said Roland Chen, MD, senior vice president, drug development, Immunology and Cardiovascular Medicines, Bristol Myers Squibb. "Camzyos is the first and only available cardiac myosin inhibitor supported by robust long-term extension and real-world effectiveness data in patients with oHCM, with clinical studies demonstrating symptom relief as well as im...